Vyome Holdings Inc. (NASDAQ:HIND) stock jumped 55% in premarket trading Wednesday after the company shared promising preclinical study results for its eye inflammation therapy, VT-1908, during the American Society for Pharmacology and Experimental Therapeutics annual meeting.
Vyome reported that its topical mycophenolate formulation showed comparable effectiveness to widely used steroids in treating anterior uveitis, the most common type of eye inflammation. The company noted that twice-daily administration of VT-1908 eye drops reduced uveitis scores at levels similar to first-line steroid therapies.
Anterior uveitis accounts for roughly 30,000 new cases of legal blindness annually in the U.S. Current steroid treatments carry risks such as cataracts and elevated intraocular pressure, which can lead to glaucoma, highlighting a potential opportunity for alternative therapies.
“The fact that VT-1908 is as effective as a steroid is exciting as we can aim to replace steroids in the eye, which are associated with a number of complications,” said Dr. Shiladitya Sengupta, co-founder of Vyome and associate professor of medicine at Harvard Medical School.
CEO Venkat Nelabhotla stated that Vyome plans to launch a Phase 1/2 clinical trial for VT-1908 in the second half of 2026, initially targeting uveitis before considering broader applications for ocular inflammation.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.